Oncology Reviews

, Volume 1, Issue 1, pp 53–64 | Cite as

Advances in diffuse malignant peritoneal mesothelioma

  • Tristan D. Yan
  • Raffit Hassan
  • Laura Welch
  • Paul H. Sugarbaker
Review

Abstract

Malignant mesothelioma is a highly aggressive neoplasm. The incidence of malignant mesothelioma is increasing worldwide. Diffuse malignant peritoneal mesothelioma (DMPM) represents one-fourth of all mesotheliomas. Association of asbestos exposure with DMPM has been observed, especially in males. A great majority of patients present with abdominal pain and distension, caused by accumulation of tumors and ascitic fluid. In the past, DMPM was considered a pre-terminal condition; therefore attracted little attention. Patients invariably died from their disease within a year. Recently, several prospective trials have demonstrated median survival of 40 to 90 months and 5-year survival of 30% to 60% after the combined treatment using cytoreductive surgery and perioperative intraperitoneal chemotherapy. This improvement in survival has prompted new searches into the medical science related to DMPM, a disease previously ignored as uninteresting. This review article focuses on the key advances in the epidemiology, diagnosis, staging, treatments and prognosis of DMPM that have occurred in the past decade.

Key words

Peritoneal mesothelioma Asbestos Cytoreductive surgery Peritonectomy Intraperitoneal chemotherapy Mesothelin Doxorubicin Cisplatin Pemetrexed 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Battifora H, McCaughey W (1994) Tumors of the Serosal Membranes. Washington, DC (USA): Armed Forces Institute of PathologyGoogle Scholar
  2. 2.
    Robinson BWS, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353:1591–1603PubMedCrossRefGoogle Scholar
  3. 3.
    Miller J, Wynn H (1908) A malignant tumor arising from the endothelium of the peritoneum and producing a mucoid ascitic fluid. J Pathol Bacteriol 12:267CrossRefGoogle Scholar
  4. 4.
    Chailleux E, Dabouis G, Pioche D et al (1988) Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 93:159–162PubMedGoogle Scholar
  5. 5.
    Antman K, Shemin R, Ryan L et al (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 6:147–153PubMedGoogle Scholar
  6. 6.
    Sridhar KS, Doria R, Raub WA Jr, et al (1992) New strategies are needed in diffuse malignant mesothelioma. Cancer 70:2969–2979PubMedCrossRefGoogle Scholar
  7. 7.
    Markman M, Kelsen D (1992) Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118:547–550PubMedCrossRefGoogle Scholar
  8. 8.
    Yates DH, Corrin B, Stidolph PN, Browne K (1997) Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 52:507–512PubMedCrossRefGoogle Scholar
  9. 9.
    Neumann V, Muller KM, Fischer M (1999) Peritoneal mesothelioma—incidence and etiology. Pathologe 20:169–176PubMedCrossRefGoogle Scholar
  10. 10.
    Eltabbakh GH, Piver MS, Hempling RE et al (1999) Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 70:6–12PubMedCrossRefGoogle Scholar
  11. 11.
    Sugarbaker PH, Welch LS, Mohamed F, Glehen O (2003) A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 12:605–621PubMedCrossRefGoogle Scholar
  12. 12.
    Yan TD, Brun EA, Cerruto CA, et al (2007) Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 14:41–49PubMedCrossRefGoogle Scholar
  13. 13.
    Park BJ, Alexander HR, Libutti SK et al (1999) Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 6:582–590PubMedCrossRefGoogle Scholar
  14. 14.
    Feldman AL, Libutti SK, Pingpank JF et al (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21:4560–4567PubMedCrossRefGoogle Scholar
  15. 15.
    Nonaka D, Kusamura S, Baratti D et al (2005) Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer 104:2181–2188PubMedCrossRefGoogle Scholar
  16. 16.
    Deraco M, Nonaka D, Baratti D et al (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13:229–237PubMedCrossRefGoogle Scholar
  17. 17.
    Brigand C, Monneuse O, Mohamed F et al (2006) Malignant peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal chemohyperthermia: Results of a prospective study. Ann Surg Oncol 13:405–412PubMedCrossRefGoogle Scholar
  18. 18.
    Loggie BW, Fleming RA, McQuellon RP et al (2001) Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67:999–1003PubMedGoogle Scholar
  19. 19.
    Yan TD, Yoo D, Sugarbaker P (2006) Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 32:948–953PubMedCrossRefGoogle Scholar
  20. 20.
    Welch LS, Acherman YIZ, Haile E et al (2005) Asbestos and peritoneal mesothelioma among college-educated men. Int J Occup Environ Health 11:254–258PubMedGoogle Scholar
  21. 21.
    Price B, Ware A (2004) Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 159:107–112PubMedCrossRefGoogle Scholar
  22. 22.
    Spirtas R, Heineman EF, Bernstein L et al (1994) Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 51:804–811PubMedGoogle Scholar
  23. 23.
    Weill H, Hughes JM, Churg AM (2004) Changing trends in US mesothelioma incidence. Occup Environ Med 61:438–441PubMedCrossRefGoogle Scholar
  24. 24.
    Montanaro F, Bray F, Gennaro V et al (2003) Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control 14:791–803PubMedCrossRefGoogle Scholar
  25. 25.
    Langard S (2005) Nordic experience: expected decline in the incidence of mesotheliomas resulting from ceased exposure? Medicina del Lavoro 96:304–311PubMedGoogle Scholar
  26. 26.
    Swuste P, Burdorf A, Ruers B (2004) Asbestos, asbestos-related diseases, and compensation claims in The Netherlands. Int J Occup Environ Health 10:159–165PubMedGoogle Scholar
  27. 27.
    McElvenny DM, Darnton AJ, Price MJ, Hodgson JT (2005) Mesothelioma mortality in Great Britain from 1968 to 2001. Occup Med (Oxford) 55:79–87CrossRefGoogle Scholar
  28. 28.
    Ulvestad B, Kjaerheim K, Moller B, Andersen A (2003) Incidence trends of mesothelioma in Norway, 1965–1999. Int J Cancer 107:94–98PubMedCrossRefGoogle Scholar
  29. 29.
    La Vecchia C, Decarli A, Peto J et al (2000) An age, period and cohort analysis of pleural cancer mortality in Europe. Eur J Cancer Prev 9:179–184PubMedCrossRefGoogle Scholar
  30. 30.
    Banaei A, Auvert B, Goldberg M et al (2000) Future trends in mortality of French men from mesothelioma. Occup Environ Med 57:488–494PubMedCrossRefGoogle Scholar
  31. 31.
    Marinaccio A, Montanaro F, Mastrantonio M et al (2005) Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models. Int J Cancer 115:142–147PubMedCrossRefGoogle Scholar
  32. 32.
    Dave SK, Beckett WS (2005) Occupational asbestos exposure and predictable asbestos-related diseases in India. Am J Ind Med 48:137–143PubMedCrossRefGoogle Scholar
  33. 33.
    Kazan-Allen L (2005) Asbestos and mesothelioma: worldwide trends. Lung Cancer 49[Suppl 1]:S3–S8PubMedCrossRefGoogle Scholar
  34. 34.
    Chang KC, Leung CC, Tam CM et al (2006) Malignant mesothelioma in Hong Kong. Respir Med 100:75–82PubMedCrossRefGoogle Scholar
  35. 35.
    Antman KH, Corson JM, Li FP et al (1983) Malignant mesothelioma following radiation exposure. J Clin Oncol 1:695–700PubMedGoogle Scholar
  36. 36.
    Chahinian AP, Pajak TF, Holland JF et al (1982) Diffuse malignant mesothelioma-prospective evaluation of 69 patients. Ann Int Med 96:746–755PubMedGoogle Scholar
  37. 37.
    Riddell RH, Goodman MJ, Moossa AR (1981) Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. Cancer 48:134–139PubMedCrossRefGoogle Scholar
  38. 38.
    Maurer R, Egloff B (1975) Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 36:1381–1385PubMedCrossRefGoogle Scholar
  39. 39.
    Peterson JT Jr, Greenberg SD, Buffler PA (1984) Non-asbestos-related malignant mesothelioma. A review. Cancer 54:951–960Google Scholar
  40. 40.
    Acherman YIZ, Welch LS, Bromley CM, Sugarbaker PH (2003) Clinical presentation of peritoneal mesothelioma. Tumori 89:269–273PubMedGoogle Scholar
  41. 41.
    Tejido Garcia R, Anta Fernandez M, Hernandez Hernandez JL et al (1997) Anales de Medicina Interna 14:573–575PubMedGoogle Scholar
  42. 42.
    Reuter K, Raptopoulos V, Reale F et al (1983) Diagnosis of peritoneal mesothelioma: computed tomography, sonography, and fine-needle aspiration biopsy. AJR Am J Roentgenol 140:1189–1194PubMedGoogle Scholar
  43. 43.
    Ros PR, Yuschok TJ, Buck JL et al (1991) Peritoneal mesothelioma. Radiologic appearances correlated with histology. Acta Radiologica 32:355–358PubMedCrossRefGoogle Scholar
  44. 44.
    Guest PJ, Reznek RH, Selleslag D et al (1992) Peritoneal mesothelioma: the role of computed tomography in diagnosis and follow up. Clin Radiol 45:79–84PubMedCrossRefGoogle Scholar
  45. 45.
    Yan TD, Haveric N, Carmignani CP et al (2005) Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori 91:394–400PubMedGoogle Scholar
  46. 46.
    Yu GH, Soma L, Hahn S, Friedberg JS (2001) Changing clinical course of patients with malignant mesothelioma: implications for FNA cytology and utility of immunocytochemical staining. Diag Cytopathol 24:322–327CrossRefGoogle Scholar
  47. 47.
    Muensterer OJ, Averbach AM, Jacquet P et al (1997) Malignant peritoneal mesothelioma. Case-report demonstrating pitfalls of diagnostic laparoscopy. Int Surg 82:240–243.PubMedGoogle Scholar
  48. 48.
    Kebapci M, Vardareli E, Adapinar B, Acikalin M (2003) CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 13:2620–2626PubMedCrossRefGoogle Scholar
  49. 49.
    Simsek H, Kadayifci A, Okan E (1996) Importance of serum CA 125 levels in malignant peritoneal mesothelioma. Tumour Biol 17:1–4PubMedGoogle Scholar
  50. 50.
    Hassan R, Bera T, Pastan I (2004) Mesothelin: a new target for immunotherapy. [see comment]. Clin Cancer Res 10:3937–3942PubMedCrossRefGoogle Scholar
  51. 51.
    Hassan R, Remaley AT, Sampson ML et al (2006) Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12:447–453PubMedCrossRefGoogle Scholar
  52. 52.
    Robinson BWS, Creaney J, Lake R et al (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612–1616PubMedCrossRefGoogle Scholar
  53. 53.
    Pass HI, Lott D, Lonardo F et al (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564–1573PubMedCrossRefGoogle Scholar
  54. 54.
    Janne PA, Wozniak AJ, Belani CP et al (2005) Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 7:40–46PubMedCrossRefGoogle Scholar
  55. 55.
    Markman M (1990) Intraperitoneal belly bath chemotherapy. 2nd ed, Chicago, Percept PressGoogle Scholar
  56. 56.
    Vlasveld LT, Gallee MP, Rodenhuis S, Taal BG (1991) Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Cancer 27:732–734PubMedGoogle Scholar
  57. 57.
    Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743PubMedCrossRefGoogle Scholar
  58. 58.
    Verwaal VJ, van Ruth S, Witkamp A, et al (2005) Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 12:65–71PubMedCrossRefGoogle Scholar
  59. 59.
    Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292PubMedCrossRefGoogle Scholar
  60. 60.
    Glehen O, Mithieux F, Osinsky D et al (2003) Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 21:799–806PubMedCrossRefGoogle Scholar
  61. 61.
    Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69–76PubMedCrossRefGoogle Scholar
  62. 62.
    Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34PubMedCrossRefGoogle Scholar
  63. 63.
    Sugarbaker P (1995) Peritonectomy procedures Ann Surg 221:29–42Google Scholar
  64. 64.
    Katz MH, Barone RM (2003) The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am 12:673–688PubMedCrossRefGoogle Scholar
  65. 65.
    Sugarbaker P, Cunliffe W, Belliveau J et al (1988) Rationale for perioperative intraperitoneal chemotherapy as a surgical adjunct for gastrointestinal malignancy. Reg Cancer Treat pp. 66–79Google Scholar
  66. 66.
    Armour EP, McEachern D et al (1993) Sensitivity of human cells to mild hyperthermia. Cancer Res 53:2740–2744PubMedGoogle Scholar
  67. 67.
    Los G, Smals OA, van Vugt MJ et al (1992) A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 52:1252–1258PubMedGoogle Scholar
  68. 68.
    Los G, Sminia P, Wondergem J et al (1991) Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27:472–477PubMedCrossRefGoogle Scholar
  69. 69.
    van de Vaart PJ, van der Vange N, Zoetmulder FA et al (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34:148–154PubMedCrossRefGoogle Scholar
  70. 70.
    Urano M, Kuroda M, Nishimura Y (1999) For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 15:79–107PubMedCrossRefGoogle Scholar
  71. 71.
    Taub RN, Hesdorffer ME, Keohan ML (2005) Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for malignant peritoneal mesothelioma (MPM). J Clin Oncol 664sGoogle Scholar
  72. 72.
    Freedman RS, Vadhan-Raj S, Butts C et al (2003) Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 9:5228–5237PubMedGoogle Scholar
  73. 73.
    Lenzi R, Rosenblum M, Verschraegen C et al (2002) Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8:3686–3695PubMedGoogle Scholar
  74. 74.
    Hassan R, Bullock S, Kindler H, Pastan I (2004) Updated results of the phase I study of SS1(dsFv)PE38 for targeted therapy of mesothelin expressing cancers. Eur J Cancer 2:280Google Scholar
  75. 75.
    Sebbag G, Yan H, Shmookler BM et al (2000) Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 87:1587–1593PubMedCrossRefGoogle Scholar
  76. 76.
    Yan TD, Popa E, Brun EA et al (2006) Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 93:1536–1542PubMedCrossRefGoogle Scholar
  77. 77.
    Yan TD, Haveric N, Carmignani CP et al (2005) Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 103:839–849PubMedCrossRefGoogle Scholar
  78. 78.
    Goldblum J, Hart WR (1995) Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol 19:1124–1137PubMedCrossRefGoogle Scholar
  79. 79.
    Kerrigan SA, Turnnir RT, Clement PB et al (2002) Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 94:378–385PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Tristan D. Yan
    • 1
  • Raffit Hassan
    • 2
  • Laura Welch
    • 3
  • Paul H. Sugarbaker
    • 1
  1. 1.Peritoneal Surface Malignancy Program, Washington Cancer InstituteWashington Hospital CenterWashington, DCUSA
  2. 2.Laboratory of Molecular Biology, Center for Cancer Research, National Cancer InstituteNational Institute of HealthBethesdaUSA
  3. 3.Center to Protect Worker’s RightsSilver SpringUSA

Personalised recommendations